Summary Compilation of Medication use in Malaysia

FORMULARI UBAT-UBATAN, KEMENTERIAN KESIHATAN MALAYSIA /
MINISTRY OF HEALTH MEDICINES FORMULARY
Generic Name FUKKM System/Group MDC NEML Method of Purchase Category Indications Dosage
Antiretroviral combination therapy of HIV infection in adults and
adolescents from 12 years of age with the following criteria: i)Patients ADULTS & ADOLESCENT (> 12 years of age): Recommended dose is one
Abacavir Sulphate 600 mg and J05AR02964
Antiinfectives Yes LPO A* unsuitable or failed other HAART treatment ii)Patients who are at high tablet once daily. Not to be used in adults or adolescents weigh less than
Lamivudine 300 mg Tablet T1001XX
risk of renal impairment iii)Patients with osteoporosis or at high risk of 40kg. CHILDREN : Not recommended
bone loss

Only for treatment of: i) Non insulin dependent diabetes mellitus (NIDDM)
when diet therapy is insufficient ii) Non insulin dependent diabetes
mellitus (NIDDM) in combination with existing conventional oral therapy
A10BF01000 where glycaemic control is inadequate Restriction: i) As second/third line Initially 50 mg daily, increase to 3 times daily up to 100 mg 3 times daily.
Acarbose 50 mg Tablet Endocrine No Government Contract A/KK
T1001XX treatment of diabetes type 2, with HBA1c < 8%. ii) For patient who have Max 200 mg 3 times daily
postprandial hyperglycemia when treated with combination of available
oral anti-diabetic/insulin. iii) The use of acarbose should be reviewed 6
months after initiation and stopped if HBA1c reduction is less than 0.5%.

S01EC01000 Reduction of intraocular pressure in open-angle glaucoma, secondary 250mg 1-4 times a day, the dosage being titrated according to patient
Acetazolamide 250 mg Tablet Ophthalmology Yes APPL B
T1001XX glaucoma and peri-operatively in angle-closure glaucoma response

S01EC01000 Reduction of intra-ocular pressure in open-angle glaucoma, secondary Adult : 250-1000mg per 24hours, usually in divided doses for amounts
Acetazolamide 500 mg Injection Ophthalmology Yes LPO B
P4001XX glaucoma and peri-operatively in angle-closure glaucoma over 250mg daily

Diluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in 200 ml
Acetylcysteine 200 mg/ml V03AB23520
Emergency Yes LPO A* Antidote for paracetamol poisoning over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours, followed by
Injection P3001XX
100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour
Acetylsalicylic Acid 100 mg, B01AC06259 Prevention of myocardial infarct, stroke, vascular occlusion and deep vein
Cardiovascular No Government Contract B 1 tablet daily
Glycine 45 mg Tablet T1001XX thrombosis. Transient ischaemic attacks
Acetylsalicylic Acid 300 mg Soluble N02BA01000 300 - 900 mg every 4 - 6 hours as required. Max 4 g daily. Use in children
Analgesics Yes APPL C Mild to moderate pain
Tablet T4001XX not recommended
ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to
i) Severe form of psoriasis including erythrodermic psoriasis and local or response, usually within range 25-50 mg daily for further 6-8 weeks
D05BB02000 generalized pustular psoriasis. ii) Severe disorders of keratinization, such (max: 75 mg daily). In disorders of keratinization, maintenance therapy of
Acitretin 10 mg Capsule Dermatology Yes LPO A*
C1001XX as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg
disorders of keratinization which may be resistant to other therapies daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited
periods
ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to
i) Severe form of psoriasis including erythrodermic psoriasis and local or response, usually within range 25-50 mg daily for further 6-8 weeks
D05BB02000 generalized pustular psoriasis. ii) Severe disorders of keratinization, such (max: 75 mg daily). In disorders of keratinization, maintenance therapy of
Acitretin 25 mg Capsule Dermatology Yes LPO A*
C1002XX as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg
disorders of keratinization which may be resistant to other therapies daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited
periods
D08AA0300
Acriflavine 0.1% Lotion Dermatology Yes APPL C+ Infected skin, lesions, cuts, abrasions, wounds and burns. Apply undiluted three times daily to the affected part .
0L6001XX
i) ADULT: 500 mcg IV daily for max of 5 days. CHILD: 1.5 mg/m2 once
Actinomycin D (Dactinomycin) 500 L01DA01110 every 3 weeks (if weight less than 10 kg, 50 mcg/kg) ii) 500 mcg IV on
Haematology/Oncology Yes LPO A i) For solid tumours ii) Gestational trophoblastic disease
mcg/ml Injection P4001XX Days 2, 4, 6, 8, 10, repeat every 7 - 10 days or 500 mcg IV bolus on Days 1
and 2, repeat every 15 days
i) Mucocutaneous Herpes Simplex infection in immunocompromised and
AIDS patients ii) Primary and recurrent Varicella Zoster infection in i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2
immunocompromised and AIDS patients iii) Severe Kaposi Varicella years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times
Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2
J05AB01000 Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5
Acyclovir 200 mg Tablet Antiinfectives Yes APPL A/KK
T1001XX gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four
and complicated varicella infection (eg. Encephalitis, purpura fulminans) times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less
vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times
fulminans, immunocompromised patients and facial, sacral and motor daily
zoster)
i) Mucocutaneous Herpes Simplex infection in immunocompromised and
AIDS patients ii) Primary and recurrent Varicella Zoster infection in i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2
immunocompromised and AIDS patients iii) Severe Kaposi Varicella years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times
Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD : less than 2
J05AB01000 Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, years, half adult dose; more than 2 years, adult dose. v) ADULT: 800 mg 5
Acyclovir 200 mg/5 ml Suspension Antiinfectives Yes LPO A*
L8001XX gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four
and complicated varicella infection (eg. Encephalitis, purpura fulminans) times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD: less
vi) Severe zoster infection in paediatrics (eg.Encephalitis, purpura than 2 years; 400mg 4 times daily, more than 2 years; 800 mg 4 times
fulminans, immunocompromised patients and facial, sacral and motor daily
zoster)

ADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg
every 8 hourly in varicella-zoster in the immunocompromised and in
simplex encephalitis (usually given for at least 10 days in encephalitis;
possibly for 14 - 21 days). NEONATE & INFANT up to 3 months with
J05AB01000 Treatment and prophylaxis of herpes simplex in immunocompromised, disseminated herpes simplex: 20mg/kg every 8 hourly for 14 days (21
Acyclovir 250 mg Injection Antiinfectives Yes APPL A*
P4001XX severe initial genital herpes and Varicella -Zoster days in CNS involvement), varicella-zoster 10-20mg/kg every 8 hourly
usually for 7 days. CHILD, 3 months - 12 years: Herpes simplex or
Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500 mg/m2 8
hourly for varicella-zoster in the immunocompromised and in simplex
encephalitis (usually given for 10 days in encephalitis)

S01AD03000
Acyclovir 3% Eye Ointment Ophthalmology Yes LPO A* Only for the treatment of herpes simplex keratitis Apply 1 cm 5 times daily. Continue for at least 3 days after healing
G5101XX
D06BB03000 Herpes simplex infections of the skin, including initial and recurrent labial
Acyclovir 5% Cream Dermatology No LPO A* Apply every 4 hours for 5 - 10 days
G1001XX and genital herpes simplex infections
i) Mucocutaneous Herpes Simplex infection in immunocompromised and
AIDS patients ii) Primary and recurrent Varicella Zoster infection in i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2
immunocompromised and AIDS patients iii) Severe Kaposi Varicella years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times
Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2
J05AB01000 Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5
Acyclovir 800 mg Tablet Antiinfectives Yes LPO A/KK
T1002XX gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four
and complicated varicella infection (eg. Encephalitis, purpura fulminans) times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less
vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times
fulminans, immunocompromised patients and facial, sacral and motor daily
zoster)

i) Third line treatment of: - Severe rheumatoid arthritis - Psoriatic arthritis -
Ankylosing spondylitis after failure of conventional DMARDs or other
biologics ii)Treatment of adults with moderate to severe chronic plaque
psoriasis who have not responded to, have contraindication or are unable i)Severe rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis :
to tolerate phototherapy and/or systemic therapies including acitretin, Subcutaneous 40 mg every other week ii)Chronic plaque psoriasis : Initial,
methotreaxate and cyclosporine iii) Crohn's Disease a) For treatment of 80 mg SC, followed by 40 mg SC every other week starting one week after
L04AB04000 moderately to severely active Crohn?s Disease in adult patients who have the initial dose iii) & iv) Crohn?s disease & Ulcerative colitis: 160mg at
Adalimumab 40 mg Injection Rheumatology No Government Contract A*
P5001XX inadequate response to conventional therapy b) For treatment of week 0 (dose can be administered as four injections in one day or as two
moderately to severely active Crohn?s Disease in adult patients who have injections per day for two consecutive days) and 80mg at week 2. After
lost response to or are intolerant to infliximab iv) Ulcerative Colitis - For induction treatment, the recommended maintenance dose is 40mg every
treatment of moderately to severely active ulcerative colitis in adult other week via subcutaneous injection.
patients who have had an inadequate response to conventional therapy
including corticosteroids and 6-mercaptopurine or azathioprine, or who
are intolerant to or have medical contraindications for such therapies




Updated July 2018 1

, FORMULARI UBAT-UBATAN, KEMENTERIAN KESIHATAN MALAYSIA /
MINISTRY OF HEALTH MEDICINES FORMULARY
Generic Name FUKKM System/Group MDC NEML Method of Purchase Category Indications Dosage
Acne vulgaris where comedones, papules and pustules predominate in
D10AD0300
Adapalene 0.1% Cream Dermatology Yes LPO A* those sensitive to benzoyl peroxide or topical tretinoin [third line Apply once daily to the affected areas after washing at bedtime
0G1001XX
treatment]
Acne vulgaris where comedones, papules and pustules predominate in
D10AD0300
Adapalene 0.1% Gel Dermatology Yes LPO A/KK those sensitive to benzoyl peroxide or topical tretinoin [third line Apply once daily to the affected areas after washing at bedtime
0G3001XX
treatment]
i) Treatment of chronic HBeAg positive and HBeAg negative hepatitis B
infection in adults with compensated liver function (lamivudine should be Adult (18-65 years): 10mg Once Daily Renal Dose Adjustment : 10mg
J05AF08000
Adefovir Dipivoxil 10 mg Tablet Antiinfectives No LPO A* tried first) ii) Lamivudine-resistant chronic hepatitis B virus infection with every 48hours (30-49ml/min); 10mg every 72hours (10-29ml/min); 10mg
T1001XX
either compensated or decompensated hepatitis function (only by every 7 days (Hemodialysis)
hepatologist and gastroenterologist for approved indications)

ADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second
dose: If the first dose does not result in elimination of the
C01EB10000 Rapid conversion of paroxysmal supraventricular tachycardia to sinus supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given
Adenosine 3 mg/ml Injection Cardiovascular No LPO B
P3001XX rhythm also as a rapid IV bolus. Third dose: If the second dose does not result in
elimination of the supraventicular tachycardia with in 1-2 minutes, 12 mg
should be given also as a rapid IV bolus
Adrenaline Acid (Epinephrine) C01CA24123 1 mg by intravenous injection repeated every 3-5 minutes according to
Cardiovascular Yes APPL B Cardiopulmonary resuscitation
Tartrate 1 mg/ml Injection P3001XX response
i) The recommended dose is 2mg aflibercept, equivalent to 0.05mL (50
i) Treatment of neovascular (wet) age-related macular degeneration (wet μL) given as intra-vitreal injection. Aflibercept treatment is initiated with
AMD). ii) Visual impairment due to diabetic macular edema (DME). one injection per month for three consecutive doses, followed by one
Aflibercept 40mg/ml solution vial S01LA05000
Ophthalmology No LPO A* Prescribing restriction: a) Treatment of naive patients with visual acuity injection every two months. ii) 2 mg aflibercept (equivalent to 50
for injection P3001XX
equal or worse than 20/50; or b) Patients with poor response to microliters) administered by intravitreal injection monthly for the first 5
treatment with ranibizumab. consecutive doses, followed by one injection every 2 months. There is no
requirement for monitoring between injections.
N06AX22000 The recommended dose is 25mg once daily at bedtime, maybe increased
Agomelatine 25 mg Tablet Psychiatry No LPO A* Major depression
T1001XX to 50mg once daily at bedtime.
i)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2
P02CA03000 i) Single or mixed infestations of intestinal parasites ii) Strongyloides
Albendazole 200 mg Tablet Antiinfectives Yes APPL C+ years: 400mg as a single dose for 3 consecutive days; Child 12 -
T1001XX infection
24months: 200mg as a single dose for 3 consecutive days

i)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2
Albendazole 200 mg/5 ml P02CA03000 i) Single or mixed infestations of intestinal parasites ii) Strongyloides
Antiinfectives Yes APPL C+ years: 400mg as a single dose for 3 consecutive days; Child 12 -
Suspension L8001XX infection
24months: 200mg as a single dose for 3 consecutive days
D08AX08000
Alcohol 70% Solution Dermatology Yes LPO C+ Use as antiseptic and disinfectant Apply to the skin undiluted or when needed
L9901XX
1 tablet once weekly [70mg/5600 IU]. Patient should receive
Osteoporosis in postmenopausal women with a history of vertebral
supplemental calcium or vitamin D, if dietary vitamin D inadequate. The
fracture and whom oestrogen replacement therapy is contraindicated.
tablet should be taken at least half and hour before the first food,
Review treatment after 2 years and if there is positive response,
Alendronate Sodium 70 mg and M05BB0397 beverage, or medication of the day with plain water only. To facilitate
Endocrine No Government Contract A* treatment may be continued up to 5 years and then re-evaluate.
Cholecalciferol 5600 IU Tablet 2T1002XX delivery to stomach and thus reduce the potential for esophageal
Treatment should be stopped if there is no positive response after 5
irritation, it should only be swallowed upon arising for the day with a full
years. Otherwise, patient needs to be given drug holiday for 1 to 2 years
glass of water and patient should not lie down for at least 30 minutes
and then continue treatment shall the benefit outweigh the risk.
and until after their first food of the day.

Osteoporosis in postmenopausal women with a history of vertebral
fracture and whom oestrogen replacement therapy is contraindicated.
70 mg once weekly. Swallow the tablet whole with a full glass of plain
Review treatment after 2 years and if there is positive response,
M05BA0452 water only on an empty stomach at least 30 minutes before breakfast
Alendronate Sodium 70 mg Tablet Endocrine No LPO A* treatment may be continued up to 5 years and then re-evaluate.
0T1001XX (and any other oral medication); stand or sit upright for at least 30
Treatment should be stopped if there is no positive response after 5
minutes and do not lie down until after eating breakfast
years. Otherwise, patient needs to be given drug holiday for 1 to 2 years
and then continue treatment shall the benefit outweigh the risk.
i) Renal osteodystrophy in patients on haemodialysis ii)
Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily;
Nutrition and Blood A11CC03000 Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the
Alfacalcidol 0.25 mcg Capsule No APPL A/KK CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose :
Disorder C1001XX management of tertiary hyperparathyroidism iv) Rickets and
0.25 mcg to 2 mcg daily
osteomalacia v) Osteoporosis
i) Renal osteodystrophy in patients on haemodialysis ii)
Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily;
Nutrition and Blood A11CC03000 Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the
Alfacalcidol 1 mcg Capsule No LPO A/KK CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose :
Disorder C1002XX management of tertiary hyperparathyroidism iv) Rickets and
0.25 mcg to 2 mcg daily
osteomalacia v) Osteoporosis
i) Renal osteodystrophy in patients on haemodialysis ii)
Nutrition and Blood A11CC03000 Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the
Alfacalcidol 2 mcg/ml Drops No LPO A* NEONATES : 0.1 mcg/kg/day
Disorder D5001XX management of tertiary hyperparathyroidism iv) Rickets and
osteomalacia v) Osteoporosis
Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii)
Adult: Initially, 1 mcg daily. Maintenance: 0.25-1 mcg daily. Child:
Nutrition and Blood A11CC03000 Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the
Alfacalcidol 2 mcg/ml Injection No LPO A* Premature infants and neonates: 0.05-0.1 mcg/kg daily; <20 kg: 0.05
Disorder P3001XX management of tertiary hyperparathyroidism iv) Rickets and
mcg/kg daily. Elderly: 0.5 mcg daily.
osteomalacia v) Osteoporosis
N01AH0211 For use as short acting narcotic analgesic in short procedures and day- Initial dose: 20 - 40 mcg/kg. Supplemental dose: 15 mcg/kg or infusion
Alfentanil HCl 0.5 mg/ml Injection Analgesics No LPO A*
0P3001XX care surgical procedures 0.5 - 1.0 mcg/kg/min
G04CA01110 Treatment of functional symptoms related with benign prostatic
Alfuzosin HCl 10 mg Tablet Genitourinary No Government Contract A* 10 mg once a day pre bed
T1001XX hypertrophy (BPH)
20 mg/kg of body weight administered once every 2 weeks as an
intravenous infusion. Monitoring It is suggested that patients be
monitored periodically for IgG antibody formation. Patients who
Alglucosidase alfa 5 mg/ml A16AB07000 experience Infusion-associated reactions suggestive of hypersensitivity
Miscellaneous No A* Infantile-onset Pompe disease
Injection P4001XX may be tested for IgE antibodies to alglucosidase alfa. Treated patients
who experience a decrease in benefit despite continued treatment with
Alglucosidase Alfa, in whom antibodies are suspected to play a role, may
be tested for neutralization of enzyme uptake or activity.
Ear, Nose and R01A000999
Alkaline Nasal Douche No LPO B To remove nasal plug To be diluted with an equal volume of warm water before use
Oropharynx L5001XX
i) Frequent and disabling attacks of gouty arthritis (3 or more
attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii)
M04AA0100 Initial dose : 100-300 mg daily. Maintenance : 300-600 mg daily.
Allopurinol 100 mg Tablet Rheumatology Yes LPO A/KK The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate
0T1002XX Maximum: 900 mg daily
nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for
lymphoma or leukaemia
i) Frequent and disabling attacks of gouty arthritis (3 or more
attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii)
M04AA0100 Initial dose : 100-300 mg daily. Maintenance : 300-600 mg daily.
Allopurinol 300 mg Tablet Rheumatology Yes APPL A/KK The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate
0T1001XX Maximum: 900 mg daily
nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for
lymphoma or leukaemia
Induction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45 mg/m2
All-Trans Retinoic Acid 10 mg L01XX14000
Haematology/Oncology No LPO A* Acute promyelocytic leukaemia daily for 2 weeks every 3 months. Renal/or hepatic insufficiency:
Capsule C1001XX
25mg/m2 daily for 30-90 days. Refer to protocols
0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily),
N05BA12000
Alprazolam 0.25 mg Tablet Psychiatry No LPO A/KK Anxiety disorders increased if necessary to a total dose of 3 mg/day. Not recommended for
T1001XX
children
0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily),
N05BA12000
Alprazolam 0.5 mg Tablet Psychiatry No LPO A Anxiety disorders increased if necessary to a total dose of 3 mg/day. Not recommended for
T1002XX
children
0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily),
N05BA12000
Alprazolam 1 mg Tablet Psychiatry No LPO A Anxiety disorders increased if necessary to a total dose of 3 mg/day. Not recommended for
T1003XX
children



Updated July 2018 2

, FORMULARI UBAT-UBATAN, KEMENTERIAN KESIHATAN MALAYSIA /
MINISTRY OF HEALTH MEDICINES FORMULARY
Generic Name FUKKM System/Group MDC NEML Method of Purchase Category Indications Dosage
C01EA01000 For treatment of congenital heart diseases which are ductus arteriosus 0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to
Alprostadil 500 mcg/ml Injection Cardiovascular No Government Contract A*
P3001XX dependent lowest effective dose
0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the
total dose administered as an initial intravenous bolus. Treatment must
B01AD02000
Alteplase 50 mg per vial Injection Cardiovascular No LPO A* Thrombolytic treatment of acute ischaemic stroke. be started as early as possible within 4.5 hours after onset of stroke
P4001XX
symptoms and after exclusion of intracranial haemorrhage by
appropriate imaging technique.
Initial dose: 100 mg daily and is increased to 100 mg twice daily (not later
N04BB01110
Amantadine HCl 100 mg Capsule Neurology No LPO B Parkinson's disease than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100
C1001XX
mg at intervals of more than 1 day
ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum:
J01GB06183 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day.
Amikacin 125 mg/ml Injection Antiinfectives No APPL A Infections due to susceptible organisms
P3003XX Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12
hourly. Maximum 15mg/kg/day
ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum:
J01GB06183 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day.
Amikacin 250mg/ml Injection Antiinfectives No APPL A Infections due to susceptible organisms
P3002XX Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12
hourly. Maximum 15mg/kg/day
Amiloride HCl 5 mg & C03EA01900 i) Diuretic as an adjunct to the management of oedematous states ii) i) Initially 1 - 2 tab daily adjusted according to response. Max : 4 tabs
Cardiovascular No APPL B
Hydrochlorothiazide 50 mg Tablet T1001XX Hypertension daily. ii) 1 -2 tabs daily as a single or divided dose
Nutrition and Blood B05BA01910 Dose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual
Amino Acids Injection No APPL A Source of amino acids in patients needing IV nutrition
Disorder P3001XX requirement for amino acid: 1-2 g/kg/day
Amino Acids with Electrolytes Nutrition and Blood B05BA10910 Dose to be individualised. ADULT usual requirement for amino acid 1-2
No LPO A Source of amino acids and electrolytes in patients needing IV nutrition
Injection Disorder P3002XX g/kg/day
Amino Acids with Glucose with Nutrition and Blood B05BA10910 Source of amino acids, carbohydrate and electrolytes in patients needing Dose to be individualised. ADULT usual requirement for amino acid 1-2
No A
Electrolytes Injection Disorder P3003XX IV nutrition g/kg/day, carbohydrate 4-6 g/kg/day
Dose to be individualised. ADULT: 500 - 2000 ml daily given by IV. ADULT
Amino Acids, Glucose and Lipid Nutrition and Blood B05BA10910 Source of amino acids, carbohydrate, lipid and electrolytes in patients
No LPO A usual requirement for amino acid 1-2 g/kg/ day, carbohydrate 4-6
with Electrolytes Injection Disorder P3001XX needing IV nutrition
g/kg/day, lipid 2-3 g/kg/day
Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25
mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion
R03DA05000
Aminophylline 25 mg/ml Injection Respiratory Yes APPL B Reversible airways obstruction, acute severe brochospasm dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Child: Loading dose: same as
P3001XX
adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8
mg/kg/hr.
200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for
C01BD01110
Amiodarone 200 mg Tablet Cardiovascular Yes LPO A* Arrhythmias another week. Maintenance dose, usually 200 mg daily or the minimum
T1001XX
required to control the arrhythmia
Initial infusion of 5mg/kg via large venous access over 20-120 minutes
C01BD01110
Amiodarone 50 mg/ml Injection Cardiovascular Yes LPO A* Arrhythmias when other drugs are contraindicated or ineffective with ECG monitoring; subsequent infusion given if necessary according to
P3001XX
response up to a maximum of 1.2 g in 24 hours
Treatment of psychoses, particularly acute or chronic schizophrenia Predominantly negative episodes: 50-300 mg once daily adjusted
disorders characterized by positive symptoms(e.g. delusion, according to the patient?s response. Mixed episodes with positive and
N05AL05000
Amisulpride 100 mg Tablet Psychiatry No Government Contract A* hallucinations, thought disorders) and/or negative symptoms(e.g. blunted negative symptoms: 400-800 mg/day in 2 divided doses adjusted
T1001XX
emotions, emotional and social withdrawal) including when the negative according to the patient?s response. Should be taken on an empty
symptoms predominate stomach (Preferably taken before meals)
Treatment of psychoses, particularly acute or chronic schizophrenia Predominantly negative episodes: 50-300 mg once daily adjusted
disorders characterized by positive symptoms(e.g. delusion, according to the patient?s response. Mixed episodes with positive and
N05AL05000
Amisulpride 400 mg Tablet Psychiatry No Government Contract A* hallucinations, thought disorders) and/or negative symptoms(e.g. blunted negative symptoms: 400-800 mg/day in 2 divided doses adjusted
T1002XX
emotions, emotional and social withdrawal) including when the negative according to the patient?s response. Should be taken on an empty
symptoms predominate stomach (Preferably taken before meals)
Initially 25mg 3 times a day. Maintenance: 25-100mg daily in divided
doses. Hospitalized patient: 100mg/day &gradually increase to 200-
N06AA0911
Amitriptyline HCl 25 mg Tablet Psychiatry Yes LPO B Depression 300mg/day. ADOLESCENT and ELDERLY: initially 20-30mg/day in divided
0T1001XX
doses w/ gradual increments. CHILD under 16 years are not
recommended
Doses range from amlodipine besylate 5 mg/valsartan 160 mg to
Amlodipine 10 mg and Valsartan C09DB01935 Essential hypertension in patients whose blood pressure is not adequately amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with
Cardiovascular No LPO A/KK
160 mg Tablet T1003XX controlled by monotherapy dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine
besylate 10 mg/valsartan 320 mg
C08CA01000
Amlodipine 10 mg Tablet Cardiovascular Yes Government Contract B Hypertension 5 mg once daily. Max: 10 mg once daily
T1002XX
Doses range from amlodipine besylate 5 mg/valsartan 160 mg to
Amlodipine 5 mg and Valsartan C09DB01935 Essential hypertension in patients whose blood pressure is not adequately amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with
Cardiovascular No A/KK
160 mg Tablet T1002XX controlled by monotherapy dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine
besylate 10 mg/valsartan 320 mg
C08CA01000
Amlodipine 5 mg Tablet Cardiovascular Yes Government Contract B Hypertension 5 mg once daily. Max: 10 mg once daily
T1001XX
Ammonium Bicarbonate, Tincture Ear, Nose and R05CA04900 Adults, the elderly and children over 12 years: 10- 20ml, repeated after 4
Yes LPO C Cough
Ipecac, etc Mixture Oropharynx L2101XX hours if required. Not more than 4 doses to be taken in any 24 hours.
Apply to affected nail once or sometimes twice a week after filling and
D01AE16110
Amorolfine 5 % Nail Lacquer Dermatology No LPO A* Fungal nail infections cleansing, allow to dry, treat finger nail for 6 months, toe nail for 9 - 12
L5001XX
months (review at intervals of 3 months)
Mild to Moderate infection: 25mg/kg/day (based on Amoxicillin dose) in
Amoxicillin & Clavulanate 228 J01CR02961
Antiinfectives No LPO A/KK Infections caused by susceptible organisms 2 divided dose. Severe infection: 45mg/kg/day (based on Amoxicillin
mg/5 ml Syrup F2102XX
dose) in 2 divided dose
Infections caused by susceptible organisms. Respiratory tract, skin, soft CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years:
Amoxicillin 1 g & Clavulanate 200 J01CR02961
Antiinfectives No Government Contract A tissue, GUT infection, septicaemia, peritonitis, post-operative infection & 30mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8
mg Injection P4002XX
osteomyelitis hourly
J01CA04012 Infections caused by susceptible strains of gram positive and gram ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided
Amoxicillin 250 mg Capsule Antiinfectives Yes APPL B
C1001XX negative organisms doses 8 hourly
Infections due to beta-lactamase producing strain where amoxicillin alone
Amoxicillin 500 mg & Clavulanate J01CR02961 ADULT & CHILD more than 12 years: Mild to moderate infections: 625 mg
Antiinfectives No APPL A/KK is not appropriate. Respiratory tract, skin, soft tissue, GUT infection,
125 mg Tablet T1002XX twice daily.
septicaemia, peritonitis, post-operative infection & osteomyelitis
Infections caused by susceptible organisms. Respiratory tract, skin, soft CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30
Amoxicillin 500 mg and J01CR02961
Antiinfectives No LPO A tissue, GUT infection, septicaemia, peritonitis, post-operative infection mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8
Clavulanate 100 mg Injection P4001XX
and osteomyelitis hourly
J01CA04012 Infections caused by susceptible strains of gram positive and gram ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided
Amoxicillin 500 mg Capsule Antiinfectives Yes LPO B
C1002XX negative organisms doses 8 hourly
Amoxicillin Trihydrate 125 mg/5 J01CA04012 Infections caused by susceptible strains of gram positive and gram CHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg:
Antiinfectives Yes Government Contract B
ml Syrup F1001XX negative organisms 20 - 40 mg/kg/day in 3 - 4 divided doses
S01A000801
Amphotericin B 0.15% Eye Drops Ophthalmology No LPO A Fungal infection of the cornea 1 drop hourly or 2 hourly
D2002XX
S01A000801
Amphotericin B 0.25% Eye Drops Ophthalmology No LPO A Fungal infection of the cornea 1 drop hourly or 2 hourly
D2003XX
ADULT: 0.25 mg/kg/day by IV infusion, gradually increase if tolerated to 1
J02AA01801
Amphotericin B 50 mg Injection Antiinfectives No APPL A Systemic fungal infections mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate
P4001XX
days. For neonates, lower doses are recommended

Ampicillin Sodium & Sulbactam J01CR01961 ADULT: (1-) 2-6g daily CHILDREN: (25-) 50-100mg/kg daily PREMATURE
Antiinfectives No LPO A Treatment of susceptible bacterial infections
Sodium 250 mg/5 ml Suspension F2101XX AND NEWBORNS: 25-50mg/kg daily

Ampicillin Sodium & Sulbactam J01CR01961 ADULT: 375-750mg twice daily CHILDREN AND INFANTS: 25-50mg/kg/day
Antiinfectives No Government Contract A/KK Treatment of susceptible bacterial infections
Sodium 375 mg Tablet T1001XX in 2 divided doses, if ≥ 30kg use an adult dose
ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g
Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of
Ampicillin Sodium 1g & Sulbactam J01CR01961
Antiinfectives No Government Contract A Treatment of susceptible bacterial infections surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated
Sodium 500mg Injection P4002XX
6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day in divided doses
every 12 hour


Updated July 2018 3

, FORMULARI UBAT-UBATAN, KEMENTERIAN KESIHATAN MALAYSIA /
MINISTRY OF HEALTH MEDICINES FORMULARY
Generic Name FUKKM System/Group MDC NEML Method of Purchase Category Indications Dosage

Ampicillin Sodium 500 mg & ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g
J01CR01961
Sulbactam Sodium 250 mg Antiinfectives No LPO A Treatment of susceptible bacterial infections Sulbactam per day. CHILD: 150-300mg/kg/day 6 - 8 hourly. Prophylaxis:
P4001XX
Injection 1.5 -3 g at induction of anaesthesia. May be repeated 6 - 8 hourly
250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day.
Ampicillin Sodium 500 mg J01CA01520 Treatment of susceptible bacterial infections (non beta-lactamase-
Antiinfectives Yes APPL B Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided doses.
Injection P4001XX producing organisms); meningitis
Usual children dose less than 10 years, half adult dose
Ampicillin Trihydrate 125 mg/5 ml J01CA01012 Treatment of susceptible bacterial infections (non beta-lactamase- CHILD: 50 - 100 mg/kg/day 4 times daily. Under 1 year: 62.5 - 125 mg 4
Antiinfectives Yes APPL B
Suspension F2101XX producing organisms) times daily, 1 - 10 years: 125 - 250 mg 4 times daily
L02BG03000 Hormonal therapy in breast cancer in post-menopausal women if failed
Anastrozole 1 mg Tablet Haematology/Oncology No LPO A* 1 mg daily
T1001XX /contraindicated with Tamoxifen
J02AX06000 Treatment of invasive candidiasis, including candidemia in adults when Loading dose of 200 mg on day 1, then 100 mg once daily thereafter for
Anidulafungin 100mg Injection Antiinfectives No Government Contract A*
P3001XX intolerance or resistance to Amphotericin B or Fluconazole at least 14 days after the last positive culture.
Antazoline HCl, Tetrahydrozoline
S01GA52110 Hay fever, conjunctivitis, allergic conjunctivitis, vernal keratoconjunctivitis ADULT : Instill 1 drop, 3 - 4 times daily, into the lower eyelid. CHILD 2 - 12
HCl and Benzalkonium Cloride Eye Ophthalmology No LPO A/KK
D2001XX and eczematosa years : Instill 1 drop daily or twice daily
Drops

Prevention of Rh(D) sensitisation to Rh(D)-negative woman: i)
i) Antepartum prophylaxis: The recommended dose is a single dose of
Pregnancy/delivery of Rh(D)-positive infant ii) Abortion/threatened
Anti RhD Gamma Globulin 300 300mcg administered by IV or IM injection ii) Postpartum prophylaxis:
Immunological J06BB01000 abortion, ectopic pregnancy or hydatidiform mole iii) Transplacental
mcg/2 ml Injection (150 mcg = 750 Yes APPL B 300mcg should be administered as soon as possible after delivery and no
Products and Vaccines P3001XX haemorrhage resulting from antepartum haemorrhage, amniocentesis,
IU) later than 72 hours thereafter, by IV or IM route. If the 72-hour limit is
chorionic biopsy or obstetric manipulative procedures e.g. external
exceeded, anti-Rh(D) immunoglobulin must be administered anyway.
version or abdominal trauma

i) To be used when conventional anti-rejection therapy is not successful ii)
Treatment of aplastic anaemia not responding to oxymethalone after 3
Antilymphocyte/Antithymocyte months, in which there is persistent pancytopenia with repeated attacks 10 - 30 mg/kg body weight daily. Slow IV infusion (over at least 4 hours)
Drugs Affecting L04AA03000
Immunoglobulin (from Horse) No Government Contract A* of septicaemia and bleeding. iii) Severe aplastic anaemia with the diluted in 250 - 500 ml Normal Saline. For Graft versus host disease
Immune Response P3001XX
Injection following parameters: a) Granulocyte less than 0.5x109/L b) Platelet less treatment:40 mg/kg/day
than 20x109/L c) Reticulocyte less than 20x109/L iv) As a conditioning
regime prior to transplant. v) Graft-versus-host disease treatment
Human rabies immunoglobulin: 20 iu/kg; half by IM and half by
Antirabies Immunoglobulin Immunological J06BB05000 infiltration around the wound. Equine rabies immunoglobulin: 40iu/kg of
Yes LPO B Treatment of rabies, post-exposure
Injection Products and Vaccines P3001XX body weigth in adults and children. Note: Please refer to package insert
for recommendations by the manufacturer.
i)Prophylaxis of acute graft rejection ii)Treatment of acute graft rejection i)1.0 - 1.5 mg/kg/day for 2 - 9 days after transplantation of a kidney,
Antithymocyte Immunoglobulin Drugs Affecting L04AA04000 iii)Prophylaxis of acute and chronic graft versus host disease iv)Treatment pancreas or liver, for 2 - 5 days after heart transplantation ii)1.5
No Government Contract A*
(from rabbit) Injection Immune Response P3001XX of steroid-resistant, acute graft versus host disease v)Treatment of mg/kg/day for 3 - 14 days iii)2.5 - 5.0 mg/kg/day for 4 days iv)2.5 - 5.0
aplastic anemia mg/kg/day for 5 days v)2.5 - 3.5 mg/kg/day for 5 days

Initial dose of 100ml of reconstituted antivenene given by slow
intravenous infusion (2ml/min). Subsequent dose can be given every 12
J06AA03000 Treatment of patients who exhibit manifestations of systemic
Antivenene Cobra Injection Emergency Yes APPL B hours according to the clinical symptoms. As product may differ from
P3002XX envenoming following a bite by Cobra (Naja kaouthia).
batches and manufacturer, it is strongly recommended to refer to the
product insert on dosing recommendation.

Initial dose of 30ml of reconstituted antivenene given by slow
Treatment of patients who exhibit manifestations of systemic intravenous infusion (2ml/min). Subsequent dose can be given every 6
J06AA03000
Antivenene Pit Viper Injection Emergency Yes APPL B envenoming following a bite by Malayan Pit Viper (Calloselasma hours according to the clinical symptoms. As product may differ from
P3001XX
rhodostoma). batches and manufacturer, it is strongly recommended to refer to the
product insert on dosing recommendation.
Antivenene Serum (Sea snake) J06AA03000 Treatment of patients who exhibit manifestations of systemic 1000 units by IV infusion over 1/2 to 1 hour. In severe cases 3000 -10000
Emergency Yes APPL B
1000 units Injection P3003XX envenoming following a bite by sea snake. units may be required
Treatment of patients who exhibit manifestations of systemic Recommended initial dose is 20ml by intravenous infusion. The injection
Antivenene Serum Snake J06AA03000 envenoming following a bite by Indian Cobra (Naja naja),Common Krait should be given very slowly as 5 minutes by direct slow intravenous route
Emergency Yes B
Polyvalent Injection P3004XX (Bungarus caeruleus), Russell's Viper (Daboia russelli) and Saw-scaled or 1hour by infusion. If symptoms continue, further doses are
Viper (Echis carinatus). administered as required until symptoms completely disappear.
Prevention of stroke and systemic embolism in adult patients with non-
5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally twice
valvular atrial fibrillation (NVAF), with one or more risk factors, such as
Apixaban 2.5mg film coated B01AF02000 daily in NVAF patients with at least two of the following characteristics:
Cardiovascular No LPO A* prior stroke or transient ischaemic attack (TIA); age ≥ 75 years;
tablet. T3201XX age ≥80 years old, body weight≤60kg, or serum creatinine≥1.5mg/dL
hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥
(133micromole/L).
II). Restriction: Only for renal patients.
Prevention of stroke and systemic embolism in adult patients with non-
5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally twice
valvular atrial fibrillation (NVAF), with one or more risk factors, such as
B01AF02000 daily in NVAF patients with at least two of the following characteristics:
Apixaban 5mg film coated tablet. Cardiovascular No LPO A* prior stroke or transient ischaemic attack (TIA); age ≥ 75 years;
T3202XX age ≥80 years old, body weight≤60kg, or serum creatinine≥1.5mg/dL
hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥
(133micromole/L).
II). Restriction: Only for renal patients.
In combination with other antiemetic agents for prevention of delayed
A04AD1200 125 mg 1 hour prior to chemotherapy on Day 1. To be given as part of a 3-
Aprepitant 125 mg Capsule Gastro-Intestinal No LPO A* nausea and vomiting associated with initial and repeat course of highly
0C1002XX day regimen that includes a corticosteroid and a 5-HT3 antagonist
emetogenic chemotherapy
In combination with other antiemetic agents for prevention of delayed
A04AD1200 80 mg once daily in the morning on Days 2 and Day 3. To be given as part
Aprepitant 80 mg Capsule Gastro-Intestinal No LPO A* nausea and vomitting associated with initial and repeat course of highly
0C1001XX of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist
emetogenic chemotherapy
All patients should receive a 1 ml IV test dose at least 10 minutes prior to
B02AB01000 loading dose. Initially 2 million KIU bolus followed by 2 million KIU in
Aprotinin 10,000 KIU/ml Injection Cardiovascular No LPO A* Only for Open Heart Surgery (extracorporeal circulation)
P3001XX heart-lung machine followed by a slow infusion of 500,000 KIU/hr until
end of surgery. CHILD: 20,000 KIU/kg/day
D02AX00000
Aqueous Cream Dermatology Yes LPO C+ Dry skin As a soap or apply to the skin as an emollient cream
G1001XX
i) Treatment of acute episodes of schizophrenia and for maintenance of Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar
N05AX12000
Aripiprazole 10mg Tablet Psychiatry No Government Contract A* clinical improvement during continuation therapy. ii) Treatment of acute mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at
T1001XX
manic episodes associated with bipolar I disorder intervals of not less than 24 hour

i) Treatment of acute episodes of schizophrenia and for maintenance of Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar
N05AX12000
Aripiprazole 15mg Tablet Psychiatry No Government Contract A* clinical improvement during continuation therapy. ii) Treatment of acute mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at
T1002XX
manic episodes associated with bipolar I disorder intervals of not less than 24 hour
Induction : 0.15 mg/kg/day IV until bone marrow remission. Total
induction dose ≤ 60 doses. Consolidation : 0.15 mg/kg/day IV for 25
L01XX27550 Relapsed acute promyelocytic leukaemia (APML). To be prescribed by
Arsenic Trioxide 1 mg/ml Injection Haematology/Oncology No LPO A* doses in 5 weeks (5 days per week, followed by 2 days interruption;
P3001XX consultant haematologist only
treatment should begin 3-6 weeks after completion of induction
therapy).
ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single
dose at the time of initial diagnosis, again 4 tablets after 8 hours and
Artemether 20mg + Lumefantrine P01BE52981 then 4 tablets twice daily (morning and evening) on each of the following
Antiinfectives No LPO B Acute uncomplicated falciparum malaria
120mg Tablet T1001XX two days (total course comprises 24 tablets). INFANT and CHILD weighing
5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tablets per dose,
depending on bodyweight
Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days
Treatment of acute uncomplicated Plasmodium falciparummalaria, Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days
Artesunate 100 mg and P01BF02000
Antiinfectives No LPO A resulting either from P. falciparum mono-infection or mixed infection with Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3
Mefloquine HCI 220 mg Tablet T1002XX
P. vivax. days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3
days
Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days
Treatment of acute uncomplicated Plasmodium falciparummalaria, Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days
Artesunate 25 mg and Mefloquine P01BF02000
Antiinfectives No LPO A resulting either from P. falciparum mono-infection or mixed infection with Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3
HCI 55 mg Tablet T1001XX
P. vivax. days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3
days



Updated July 2018 4